BR112021022635A2 - Formas sólidas de {6-[(2-amino-3-cloropiridin-4-il)sulfanil] 3 [(3s,4s) 4 amino-3-metil-2-oxa-8-azaespiro[4.5]decan-8-il]-5 metilpirazin 2-il}metanol, um inibidor de shp2 - Google Patents
Formas sólidas de {6-[(2-amino-3-cloropiridin-4-il)sulfanil] 3 [(3s,4s) 4 amino-3-metil-2-oxa-8-azaespiro[4.5]decan-8-il]-5 metilpirazin 2-il}metanol, um inibidor de shp2Info
- Publication number
- BR112021022635A2 BR112021022635A2 BR112021022635A BR112021022635A BR112021022635A2 BR 112021022635 A2 BR112021022635 A2 BR 112021022635A2 BR 112021022635 A BR112021022635 A BR 112021022635A BR 112021022635 A BR112021022635 A BR 112021022635A BR 112021022635 A2 BR112021022635 A2 BR 112021022635A2
- Authority
- BR
- Brazil
- Prior art keywords
- amino
- methylpyrazin
- decan
- azaspiro
- chloropyridin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962858837P | 2019-06-07 | 2019-06-07 | |
| PCT/US2020/036137 WO2020247643A1 (en) | 2019-06-07 | 2020-06-04 | Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, an shp2 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021022635A2 true BR112021022635A2 (pt) | 2022-01-04 |
Family
ID=71787182
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021022635A BR112021022635A2 (pt) | 2019-06-07 | 2020-06-04 | Formas sólidas de {6-[(2-amino-3-cloropiridin-4-il)sulfanil] 3 [(3s,4s) 4 amino-3-metil-2-oxa-8-azaespiro[4.5]decan-8-il]-5 metilpirazin 2-il}metanol, um inibidor de shp2 |
Country Status (15)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI852912B (zh) | 2017-09-07 | 2024-08-21 | 美商銳新醫藥公司 | Shp2抑制劑組合物以及治療癌症的方法 |
| CA3142430A1 (en) | 2019-06-07 | 2020-12-10 | Revolution Medicines, Inc. | Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, an shp2 inhibitor |
| TW202313041A (zh) | 2021-06-09 | 2023-04-01 | 瑞士商諾華公司 | 包含達拉菲尼、曲美替尼和shp2抑制劑之三重藥物組合 |
| TW202317100A (zh) | 2021-06-23 | 2023-05-01 | 瑞士商諾華公司 | 包含kras g12c抑制劑的藥物組合及其用於治療癌症之用途 |
| US20240374571A1 (en) | 2021-09-01 | 2024-11-14 | Novartis Ag | Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5262564A (en) | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
| EP1871762A2 (en) * | 2005-04-18 | 2008-01-02 | Neurogen Corporation | Subtituted heteroaryl cb1 antagonists |
| NZ623069A (en) | 2009-08-17 | 2015-11-27 | Sloan Kettering Inst Cancer | Heat shock protein binding compounds, compositions, and methods for making and using same |
| JO3517B1 (ar) * | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| ES2699351T3 (es) * | 2014-01-17 | 2019-02-08 | Novartis Ag | Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2 |
| IL311645B2 (en) | 2016-07-12 | 2025-11-01 | Revolution Medicines Inc | 2,5- disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines asallosteric shp2 inhibitors |
| TWI852912B (zh) | 2017-09-07 | 2024-08-21 | 美商銳新醫藥公司 | Shp2抑制劑組合物以及治療癌症的方法 |
| KR20200143417A (ko) | 2018-04-10 | 2020-12-23 | 레볼루션 메디슨즈, 인크. | Shp2 억제제 조성물, 암을 치료하는 방법 및 shp2 돌연변이를 갖는 대상체를 확인하는 방법 |
| CA3142430A1 (en) | 2019-06-07 | 2020-12-10 | Revolution Medicines, Inc. | Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, an shp2 inhibitor |
-
2020
- 2020-06-04 CA CA3142430A patent/CA3142430A1/en active Pending
- 2020-06-04 EP EP20746488.4A patent/EP3980128A1/en active Pending
- 2020-06-04 CN CN202080054905.0A patent/CN114190090A/zh active Pending
- 2020-06-04 MX MX2021014855A patent/MX2021014855A/es unknown
- 2020-06-04 PH PH1/2021/552902A patent/PH12021552902A1/en unknown
- 2020-06-04 KR KR1020227000184A patent/KR20220019017A/ko not_active Ceased
- 2020-06-04 TW TW109118750A patent/TW202112785A/zh unknown
- 2020-06-04 BR BR112021022635A patent/BR112021022635A2/pt not_active IP Right Cessation
- 2020-06-04 AU AU2020288631A patent/AU2020288631A1/en not_active Abandoned
- 2020-06-04 CN CN202210564150.XA patent/CN115141205A/zh active Pending
- 2020-06-04 MA MA056113A patent/MA56113A/fr unknown
- 2020-06-04 SG SG11202112461QA patent/SG11202112461QA/en unknown
- 2020-06-04 JP JP2021571896A patent/JP2022534788A/ja active Pending
- 2020-06-04 WO PCT/US2020/036137 patent/WO2020247643A1/en not_active Ceased
-
2021
- 2021-02-26 US US17/187,504 patent/US11220501B2/en active Active
- 2021-11-29 US US17/537,113 patent/US12528807B2/en active Active
- 2021-12-01 IL IL288568A patent/IL288568A/en unknown
-
2025
- 2025-06-18 JP JP2025101917A patent/JP2025138706A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MA56113A (fr) | 2022-04-13 |
| US12528807B2 (en) | 2026-01-20 |
| JP2022534788A (ja) | 2022-08-03 |
| TW202112785A (zh) | 2021-04-01 |
| MX2021014855A (es) | 2022-01-18 |
| CN115141205A (zh) | 2022-10-04 |
| EP3980128A1 (en) | 2022-04-13 |
| IL288568A (en) | 2022-02-01 |
| AU2020288631A1 (en) | 2021-12-09 |
| JP2025138706A (ja) | 2025-09-25 |
| PH12021552902A1 (en) | 2022-04-04 |
| US11220501B2 (en) | 2022-01-11 |
| CN114190090A (zh) | 2022-03-15 |
| WO2020247643A1 (en) | 2020-12-10 |
| KR20220019017A (ko) | 2022-02-15 |
| CA3142430A1 (en) | 2020-12-10 |
| US20210253574A1 (en) | 2021-08-19 |
| SG11202112461QA (en) | 2021-12-30 |
| US20220298159A1 (en) | 2022-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022004424A2 (pt) | Pró-fármacos antivirais e formulações dos mesmos | |
| BR112022009563A2 (pt) | Compostos de pirrolotriazina atuando como inibidor de mnk | |
| CR20220251A (es) | Nuevos derivados de metilquinazolinona | |
| CR20220234A (es) | Degradadores de moléculas pequeñas de helios y procedimientos de uso | |
| BRPI0515218A (pt) | composto, composição farmacêutica, método para o tratamento de um mamìfero ou ser humano, método de uso do composto, novos intermediários, uso dos novos intermediários, processo para a preparação de um composto | |
| BR112021011325A2 (pt) | Derivados de rapamicina | |
| WO2019139899A8 (en) | Benzamide compounds | |
| BR112021022536A2 (pt) | Derivado de fenilpropenilpiridina substituída e método de preparação do mesmo e uso médico do mesmo | |
| BR112012003578A8 (pt) | Composto, sal farmaceuticamente aceitável, sal de sulfato, composição farmacêutica, método para tratar uma infecção viral, e, uso de um composto ou sal | |
| BRPI0607796A2 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparação e uso do mesmo, e, composição farmacêutica | |
| EP4706761A3 (en) | Aza-, oxa and thia-pregnan-20-one-3.alpha.-ol compounds for use in treating cns disorders | |
| HN2003000348A (es) | Compuestos de benzofurano, composiciones y metodos para tratamiento y profilaxis de infeccion virales de hepatitis c y enfermedades asociadas. | |
| BR112023022050A2 (pt) | Agonistas do receptor de orexina e usos destes | |
| EP4321519A3 (en) | Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders | |
| AU2020231934A8 (en) | Compounds useful in HIV therapy | |
| MX2021002529A (es) | Analogos de illudin, usos de los mismos y metodos para sintetizar los mismos. | |
| WO2018209363A3 (en) | PROPIONIC ACID DERIVATIVES AND ASSOCIATED METHODS OF USE | |
| BR112017000246A2 (pt) | composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal | |
| PH12021552902A1 (en) | Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, an shp2 inhibitor | |
| BR112021020297A2 (pt) | Compostos de hexa-hidro-1h-pirazino[1,2-a]pirazina para o tratamento de doença autoimune | |
| AU2018274378A1 (en) | Compound used as autophagy regulator, and preparation method therefor and uses thereof | |
| MX2021012248A (es) | Polimorfos de voruciclib y metodos de elaboracion y uso de los mismos. | |
| BR112021018587A2 (pt) | Compostos de heteroaril(heterociclil)metanol úteis no tratamento de hiperglicemia | |
| WO2022104153A3 (en) | Compounds and methods for treating viral infections | |
| BR112022017779A2 (pt) | Imunomodulação de azaletos de o-het-arila |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2830 DE 01-04-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |